Heerspink HJL, Stefnsson BV, Correa-Rotter R, Chertow GM, Greene T, Hou F-F, Mann JFE, McMurray JJV, Lindberg M, Rossing P, Sjstrm CD, Toto RD, Langkilde A-M, Wheeler DC
A recent study found that GLP-1s were associated with non-scarring alopecia, a temporary form of hair loss
While both agents have demonstrated promising results in clinical trials, several factors limit the generalisability of these findings and highlight the need for continued research and clinical evaluation
We can use the example of the GLP-1 makers to illustrate these elements: Catalysts The catalysts within the narrative are the primary drivers of a companys revenue and earnings growth (or decline)
Tirzepatide has a half-life of approximately 5 days, which supports weekly administration